FUS Poised for Growth in Japan
After nearly 20 years of activity in the country, focused ultrasound may now be positioned for commercial success in Japan. There are systems installed at approximately 40 sites, and devices have been approved to treat uterine fibroids, bone metastases, and the prostate. However, reimbursement has been scant with limited usage outside the investigator-led research setting. The regulatory approval of systems to commercially treat the brain and prostate cancer may be the inflection point needed to establish the path for widespread adoption. Treating the Brain Insightec recently filed for regulatory approval to treat tremor with their ExAblate Neuro system. “The functional neurosurgeons in Japan are very open to new non-invasive technologies," said Insightec’s Country Manager for Japan, Yair Bauer. "They do not want to make incisions, and we can offer a value proposition to hospital administrators.” LEARN MORE ABOUT BRAIN FUS IN JAPAN >
"In ten years, Japan has the potential to be a leading market in the world for focused ultrasound." –Yair Bauer |
|
Treating the Prostate SonaCare Medical installed their first Sonablate system in Japan in 1998, and they now have more than 20 systems in operation there. They will soon apply for regulatory approval for prostate ablation, opening up the potential to treat cancer along with benign prostatic hyperplasia (BPH). As many as 5,000 patients have been treated in Japan with Sonablate for prostate cancer. SonaCare’s leading Japanese site is headed by Dr. Toyoaki Uchida, Tokai University, Hachioji Hospital, and the team’s largest clinical series for prostate cancer was recently published by the Journal of Urology. “Currently, the number of prostate cancer cases in Japan is roughly equivalent to that of the US,” says SonaCare CEO Mark Carol, MD, “But unlike the US where the incidence is declining, in Japan it is increasing.” Advancing Focused Ultrasound Research While Insightec and SonaCare are making progress on the regulatory front, Japanese researchers have been leading important studies in breast cancer, osteoarthritic bone pain, and other applications of the technology. READ MORE ABOUT RESEARCH IN JAPAN > |
|